Current Neuro-Oncology
Volume
24 Number 4
28 February 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 4, 28 February
Alexopoulos
G, Zhang J, Karampelas I, Patel M, Kemp J, Coppens J, Mattei TA,
Mercier P.
Long-term
time series forecasting and updates on survival analysis of
glioblastoma
multiforme, a 1975-2018 population-based study.
Neuroepidemiology.
2022 Feb 16;56(2):75-89∟.
doi: 10.1159/000522611∟.
PMID: 35172317∟.
Observational
study.
ˍ
Behling
F, Rang J, Dangel E, Noell S, Renovanz M, Mäurer I,
Schittenhelm J, Bender B, Paulsen F, Brendel B, Martus P, Gempt J,
Barz M, Meyer B, Tatagiba M, Skardelly M.
Complete
and Incomplete Resection for Progressive Glioblastoma
Prolongs
Post-Progression Survival.
Front
Oncol. 2022 Feb 16;12:755430∟.
doi: 10.3389/fonc.2022.755430∟.
PMID: 35251956∟.
Observational study. ˍ
Hart
M, Anderson-Mellies A, Beltrami A, Gilani A, Green
AL.
Population-based
analysis
of CNS tumor diagnoses, treatment, and survival in congenital and
infant
age groups.
J
Neurooncol. 2022 Feb 17∟.
doi: 10.1007/s11060-022-03967-z∟.
PMID: 35175546∟.
Observational study˰ ˍ
*
Ramos-Fresnedo
A, Pullen MW, Perez-Vega C, Domingo RA, Akinduro OO, Almeida JP,
Suarez-Meade P, Marenco-Hillembrand L, Jentoft ME, Bendok BR,
Trifiletti DM, Chaichana KL, Porter AB, Quiñones-Hinojosa
A, Burns TC, Kizilbash SH, Middlebrooks EH, Sherman WJ.
The
survival outcomes of molecular glioblastoma
IDH-wildtype:
a multicenter study.
J
Neurooncol. 2022 Feb 17∟.
doi: 10.1007/s11060-022-03960-6∟.
PMID: 35175545∟.
Observational study˰ ˍ
van
Putten EHP, Kleijn A, van Beusechem VW, Noske D, Lamers CHJ, de
Goede AL, Idema S, Hoefnagel D, Kloezeman JJ, Fueyo J, Lang FF,
Teunissen CE, Vernhout RM, Bakker C, Gerritsen W, Curiel DT, Vulto
A, Lamfers MLM, Dirven CMF.
Convection
enhanced
delivery of the oncolytic adenovirus Delta24-RGD in recurrent GBM
patients;
a phase I clinical trial including correlative studies.
Clin
Cancer Res. 2022 Feb 17;28(8):1572-1585
ˍ.
doi: 10.1158/1078-0432.CCR-21-3324∟.
PMID: 35176144∟.
Interventional study. ˍ
Gött
H, Kiez S, Dohmen H, Kolodziej M, Stein M.
Tumor
treating fields therapy
is
feasible and safe in a 3-year-old patient with diffuse midline
glioma H3K27M -
a case report.
Childs
Nerv Syst. 2022 Feb 18∟.
doi: 10.1007/s00381-022-05465-z∟.
PMID: 35181800∟.
Case report. ˍ
Chatterjee
A, Bhadane M, Manjali JJ, Dasgupta A, Epari S, Sahay A, Patil V,
Moiyadi A, Shetty P, Gupta T.
Optimizing
post-operative adjuvant therapy in
elderly
patients with newly-diagnosed glioblastoma: single-institution
audit of
clinical
outcomes from a tertiary-care comprehensive cancer centre in
India.
World
Neurosurg. 2022 Feb 19;161:e587-e595
ˍ.
doi: 10.1016/j.wneu.2022.02.059∟.
PMID: 35192971∟.
Observational study˰ ˍ
Pan
YH, Lin SZ, Chiu TL.
Biodegradable
controlled-release polymer containing
butylidenephthalide
to treat a recurrent cervical spine glioblastoma with
promising
result: a compassionate trial report.
Anticancer
Drugs. 2022 Feb 21;33(4):394-399∟.
doi: 10.1097/CAD.0000000000001275∟.
PMID: 35266889∟.
Case report˰ ˍ
Cameron
JM, Brennan PM, Antoniou G, Butler HJ, Christie L, Conn JJA,
Curran T, Gray E, Hegarty MG, Jenkinson MD, Orringer D, Palmer DS,
Sala A, Smith BR, Baker MJ.
Clinical
validation of a spectroscopic liquid biopsy for earlier
detection
of brain cancer.
Neurooncol
Adv. 2022 Feb 22;4(1):vdac024∟.
doi: 10.1093/noajnl/vdac024∟.
PMID: 35316978∟.
Observational study.
ˍ
Dono
A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G,
Takayasu T, Robell L, Majd NK, de Groot J, Esquenazi Y,
Kamiya-Matsuoka C, Ballester LY.
Molecular,
Histological, and Clinical Characteristics of
Oligodendrogliomas:
A Multi-Institutional Retrospective Study.
Neurosurgery.
2022 Feb 22∟.
doi: 10.1227/NEU.0000000000001875∟.
PMID: 35179134∟.
Observational study˰ ˍ
Löber-Handwerker
R, Döring K, Bock C, Rohde V, Malinova V.
Defining
the impact
of adjuvant treatment on the prognosis of patients with inoperable
glioblastoma
undergoing biopsy only: does the survival benefit outweigh the
treatment
effort?
Neurosurg
Rev. 2022 Feb 23∟.
doi: 10.1007/s10143-022-01754-y∟.
PMID: 35194724∟.
Observational study. ˍ
Noda
M, Inaji M, Karakama J, Arai Y, Kuroha M, Tamura K, Tanaka Y,
Maehara T.
Ischemic
Stroke with Multiple Cerebral Artery Stenosis in a Patient with an
Anaplastic
Astrocytoma during Bevacizumab Treatment: A Case Report.
NMC
Case Rep J. 2022 Feb 23;9:13-17∟.
doi: 10.2176/jns-nmc.2021-0297∟.
PMID: 35340332∟.
Case report. ˍ
Papusha
L, Zaytseva M, Panferova A, Druy A, Valiakhmetova A, Artemov A,
Salnikova E, Kislyakov A, Imyanitov E, Karachunsky A, Maschan A,
Hwang EI, Novichkova G, Packer RJ.
Two
clinically distinct cases of infant hemispheric
glioma
carrying ZCCHC8:ROS1 fusion and responding to entrectinib.
Neuro
Oncol. 2022 Feb 23;24(6):1029-1031∟.
doi: 10.1093/neuonc/noac026∟.
PMID: 35196386∟.
Case report. ˍ
Chen
D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, Liu T,
Ghiaseddin A, Rahman M, Tran DD.
Tumor
Treating Fields dually activate STING and
AIM2
inflammasomes to induce adjuvant immunity in glioblastoma.
J
Clin Invest. 2022 Feb 24;132(8):e149258∟.
doi: 10.1172/JCI149258∟.
PMID: 35199647∟.
Laboratory investigation.
ˍ
Olubajo
F, Thorpe A, Davis C, Sinha R, Crofton A, Mills SJ, Williams M,
Jenkinson MD, Price SJ, Watts C, Brodbelt AR.
Tumour
treating fields in
glioblastoma:
is the treatment tolerable, effective, and practical in UK
patients?
Br
J Neurosurg. 2022 Feb 24, 2022:1-7∟.
doi: 10.1080/02688697.2022.2028722∟.
PMID: 35200077∟.
Interventional study˰ ˍ
Vajapeyam
S, Brown D, Ziaei A, Wu S, Vezina G, Stern JS, Panigrahy A, Patay
Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Jones BV,
Yeom KW, Onar-Thomas A, Dunkel IJ, Fouladi M, Fangusaro JR,
Poussaint TY.
ADC
Histogram
Analysis
of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report
from the
Pediatric Brain Tumor Consortium.
AJNR
Am J Neuroradiol. 2022 Feb 24∟.
doi: 10.3174/ajnr.A7433∟.
PMID: 35210278∟.
Interventional study. ˍ
*
Grogan
D, Bray DP, Cosgrove M, Boucher A, Erwood A, Linder DF, Mendoza P,
Morales B, Pradilla G, Nduom EK, Neill S, Olson JJ, Hoang
KB.
Clinical
and radiographic
characteristics of diffuse astrocytic glioma, IDH-wildtype, with
molecular
features of glioblastoma: a single institution review.
J
Neurooncol. 2022 Feb 25∟.
doi: 10.1007/s11060-022-03961-5∟.
PMID: 35212929∟.
Observational study˰ ˍ
Hersh
AM, Patel J, Pennington Z, Porras JL, Goldsborough E, Antar A,
Elsamadicy AA, Lubelski D, Wolinsky JP, Jallo G, Gokaslan ZL, Lo
SL, Sciubba DM.
Perioperative
outcomes and survival after surgery for intramedullary spinal cord
tumors:
a single-institution series of 302 patients.
J
Neurosurg Spine. 2022 Feb 25, 2022:1-11∟.
doi: 10.3171/2022.1.SPINE211235∟.
PMID: 35213831∟.
Observational study˰ ˍ
Krishnan
AS, Gupta S, Mandal S, Phulware RH, Gupta M.
Metachronous
Osseous
Metastases
From Gliobliostoma Mutiforme: An Unusual Presentation.
Cureus.
2022 Feb 25;14(2):e22587∟.
doi: 10.7759/cureus.22587∟.
PMID: 35355536∟.
Case report. ˍ
van
Dijken BRJ, Ankrah AO, Stormezand GN, Dierckx RAJO, Jan van Laar
P, van der Hoorn A.
Prognostic
value of 11C-methionine volume-based PET parameters in
IDH
wild type glioblastoma.
PLoS
One. 2022 Feb 25;17(2):e0264387∟.
doi: 10.1371/journal.pone.0264387∟.
PMID: 35213602∟.
Observational study. ˍ
Bielecka-Wajdman
AM, Ludyga T, Smyk D, Smyk W, Mularska M, Świderek P,
Majewski W, Mullins CS, Linnebacher M, Obuchowicz E.
Glucose
Influences the
Response
of Glioblastoma
Cells
to Temozolomide and Dexamethasone.
Cancer
Control. 2022 Feb 26;29:10732748221075468∟.
doi: 10.1177/10732748221075468∟.
PMID: 35225010∟.
Laboratory investigation. ˍ
Omuro
A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF,
Chalamandaris AG, Potter V, Butowski N, Lim M.
Nivolumab
plus radiotherapy with
or
without temozolomide in newly diagnosed glioblastoma: Results from
exploratory
phase I cohorts of CheckMate 143.
Neurooncol
Adv. 2022 Feb 26;4(1):vdac025∟.
doi: 10.1093/noajnl/vdac025∟.
PMID: 35402913∟.
Interventional
study. ˍ
*
Liu
S, Song Y, Zhang IY, Zhang L, Gao H, Su Y, Yang Y, Yin S, Zheng Y,
Ren L, Yin HH, Pillai R, Nath A, Medina EF, Cosgrove PA, Bild AH,
Badie B.
RAGE
Inhibitors
as Alternatives to Dexamethasone for Managing Cerebral Edema
Following
Brain Tumor Surgery.
Neurotherapeutics.
2022 Feb 28∟.
doi: 10.1007/s13311-022-01207-w∟.
PMID: 35226341∟.
Laboratory investigation˰ ˍ